BioSpace

JUNE 6, 2022

In the next eight years, more than 190 drugs will go off-patent for these companies. ZS Associates' Maria Whitman provides analyses and tips. Of those, 69 are blockbuster drugs.

Drugs 69

Drugs 69

BioTech 365

JANUARY 5, 2022

Bristol Myers Squibb Selects ZS To Support Global Commercialization and Analytics Capabilities Bristol Myers Squibb Selects ZS To Support Global Commercialization and Analytics Capabilities EVANSTON, Ill.–(BUSINESS

52

52

pharmaphorum

OCTOBER 27, 2022

However, fostering lasting and meaningful partnerships is not a simple task for life science companies. Patient centricity initiatives often suffer when leadership changes and the patient-centric culture isn’t codified in KPIs, says Sharon Suchotliff, associate principal at ZS Associates. Company profile: ZS Associates.

Life Science 101

Life Science Research Development Clinical Research 101

pharmaphorum

NOVEMBER 8, 2022

Ask nearly any pharma company these days if they’re patient-centric, and you’ll probably get an answer in the affirmative. Suchotliff sat down with Deep Dive to discuss the current state of patient centricity in pharma, some of the common foibles and misconceptions, and how pharma companies can get themselves on the right track.

Life Science 52

Life Science Pharma Companies Branding Development 52

pharmaphorum

SEPTEMBER 21, 2022

That’s according to Sharon Suchotliff, patient centricity lead at consultancy firm ZS Associates, which has just published a book on the art of patient involvement. In 2019, ZS Associates carried out a global survey of pharmaceutical companies to get a better idea of patient centricity perceptions and behaviours.

Development 97

Development Regulation Drugs Production 97

Pharma Marketing Network

MARCH 20, 2022

Kumar Ritwik of ZS Pharma showcased the importance of AI and using modular content to truly customize and personalize information to the point where “less is more” in terms of engaging with your HCPs in ways they respond to.

FDA Approval 40

FDA Approval Production Marketing Drugs 40

pharmaphorum

JANUARY 24, 2022

AZ added Lokelma to its pipeline after buying ZS Pharma, the US company that developed it, for $2.7 NICE says that Lokelma can be used for non-dialysed patients with CKD or heart failure who have persistent hyperkalaemia with a potassium level of 6.0 mmol/litre or more that is preventing them from recommended treatment with RAAS drugs.

Drugs 52

Drugs Sales Doctors Doctor 52